Cost-utility analysis of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression in patients with type 2 diabetes mellitus

Abstract Background Many trials have highlighted the benefits of sodium-glucose co-transporter 2 inhibitors (SGLT2is) in terms of chronic kidney disease (CKD) progression. However, SGLT2is are high-cost medication, and their cost- effectiveness varies by setting across countries. Methods This study...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Sukanya Siriyotha, Amarit Tansawet, Oraluck Pattanaprateep, Tanawan Kongmalai, Panu Looareesuwan, Junwei Yang, Suparee W. Boonmanunt, Gareth J. McKay, John Attia, Ammarin Thakkinstian
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2026-04-01
Serier:	BMC Nephrology
Fag:	Cost-utility analysis Sodium-glucose cotransporter-2 inhibitor Chronic kidney disease
Online adgang:	https://doi.org/10.1186/s12882-026-04980-4
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!